Estrogen and visual hallucinations in a patient with Charles Bonnet syndrome.
OBJECTIVE
To describe the occurrence of visual hallucinations in a patient with Charles Bonnet syndrome associated with estrogen intake.


METHODS
Case report.


RESULTS
An 84-year-old woman with poor visual acuity secondary to bilateral, nonexudative, age-related macular degeneration had nonthreatening visual hallucinations 2 weeks after starting oral estrogen for osteoporosis. The estrogen was stopped, and the hallucinations subsided. The patient was given estrogen twice more and each time the hallucinations recurred.


CONCLUSIONS
We report a case of Charles Bonnet syndrome associated with estrogen intake in an 84-year-old woman. Estrogen may have promoted release phenomena and triggered the hallucinatory episodes in our patient.
Fernandes
L H
LH
LuEsther T. Mertz Retina Research Laboratory, Manhattan Eye, Ear, and Throat Hospital, New York, NY, USA.
Scassellati-Sforzolini
B
B
Spaide
R F
RF
D000368:Aged; D000369:Aged, 80 and over; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects*; D005260:Female; D006212:Hallucinations / Q000139:chemically induced*; D006801:Humans; D008268:Macular Degeneration / Q000150:complications; D010024:Osteoporosis / Q000188:drug therapy; D013577:Syndrome; D014786:Vision Disorders / Q000209:etiology; D014792:Visual Acuity
D004967:Estrogens